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Purpose. To examine the effects of two doses of low-frequency (12Hz), low-magnitude (0.3 g), whole body vibration on markers
of bone formation and resorption in postmenopausal women. Methods. Women were recruited and randomized into a sham
vibration control group, one time per week vibration group (1×/week), or three times per week vibration group (3×/week).
Vibration exposure consisted of 20 minutes of intermittent vibration for the 1×/week and 3×/week groups, and sham vibration
(<0.1 g) for the control group for eight weeks. Double-blinded primary outcomemeasures were urine markers of bone resorption:
N-telopeptide X normalised to creatinine (NTx/Cr) and bone formation: bone-specific alkaline phosphatase (ALP). Results. Forty-
six women (59.8± 6.2 years, median 7.3 years since menopause) were enrolled. NTx/Cr was significantly reduced (34.6%) in the
3×/wk vibration group but not in the 1×/wk vibration group compared with sham control (P < .01) group. No effect of time or
group allocation was observed on the bone formation marker ALP (P = .27). Conclusion. We have shown for the first time that
low-frequency, low-magnitude vibration 3×/week for eight weeks in postmenopausal women results in a significant reduction in
NTx/Cr, a marker of bone resorption, when compared with sham vibration exposure.
1. Introduction
Whole body vibration training is promoted as a potentially
safe, low-impact alternative to current therapeuticmodalities
to combat bone loss in older adults. Whole body vibration is
without the potential side effects of pharmacological inter-
vention or risks associated with high impact or strenuous
exercise. The mechanism of vibration stimulus on bone is
not wholly understood; however, it is hypothesized that the
anabolic effect of vibration on bone may be a result of stress
exerted on bone resulting in increased fluid flow [1], greater
activation of muscle spindles through enhanced sensitivity of
mechanoreceptors, and increased osteogenesis in osteoblasts,
suggesting that vibration is anabolic at a cellular level [2, 3].
Animal studies investigating the effects of vibration stim-
ulus on bone reported positive results, with improvements
in bone strength, formation rates, bone mineral content,
and bone mineral density (BMD) following low-magnitude,
high-frequency vibration exposure [4–8]. Human studies
have reported potential benefits in bone [9–18], muscle
function [15, 17, 19, 20], balance and prevention of falls [21],
reduction of muscle spasticity in those with cerebral palsy
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[22], and postural control in those with Parkinson’s disease
[23]. However, the optimal time course, dose, and frequency
of vibration to elicit optimal changes in bone are currently
not established, with a wide variety of vibration exposure
protocols leading to changes in bone outcomes in only a
small number of the currently published studies. Inconsis-
tency in study nomenclature, design, includingmeasurement
of bone outcomes, reporting of adverse effects, and noncom-
pliance, highlight the lack of uniformity and small pool of
information available on the effects of vibration on bone
[24]. As a result, more robust studies are required in order to
understand the effect of vibration on bone and determine the
vibration prescription to elicit the greatest beneficial effect on
bone.
In this study, we specifically examined the dose-response
relationship (frequency of exposure) of vibration stimulus
on markers of bone turnover in postmenopausal women
in a community setting. We hypothesized the application
of low-frequency, low-magnitude vibration stimulus for 8
weeks would increase the bone formation marker, ALP, and
decrease the bone resorption marker, NTx/Cr, in a dose-
dependent relationship compared with a sham vibration
exposure.
2. Methods
2.1. Participants. Postmenopausal women were recruited
from northern suburbs of Sydney, Australia by means of
advertisements in local newspapers, posters in local GPs
surgeries, letterbox drops, and advertisements to existing
members of a large suburban community club via newsletters
and posters within the club.
Participants were considered eligible if they were post-
menopausal for at least 12months; willing to continue taking
any bone altering medications or supplements they were
previously taking for the duration of the study, including
calcium, vitamin D, bisphosphonates, and hormone replace-
ment therapy (HRT); able to stand unassisted for sustained
periods of time (i.e., 20 minutes); willing to attend testing
and training sessions as determined by the researchers; able
to travel independently to and from the testing/training
venue. Exclusion criteria included cognitive impairment,
contraindications to vibration platform training (including
pacemaker and fracture within the past six months), and the
diagnosis of diseases other than osteoporosis affecting bone.
The study protocol was approved by the Human Research
Committee, University of Sydney, Australia (June 2007) and
was registered with the Australian Clinical Trials Registry
(ACTRN12607000491460). All participants gave informed
written consent prior to enrolment.
2.2. Design. The study was a randomized placebo-controlled
clinical trial, with a complete case statistical analysis design
and secondary intention-to-treat analytic strategy. The vi-
bration protocol consisted of an 8-week whole body vibra-
tion exposure program. Serum and urine markers of bone
turnover were measured at baseline and at the conclusion
of the study. All testing and training was conducted at
Freshwater Health and Fitness, Harbord Diggers-Mounties
Group, Harbord, NSW, Australia. Participants were recruited
and trained over one season (late autumn to winter 2007).
2.3. Randomization Method, Concealment, Allocation, and
Implementation. Participants were randomized into the
Sham group, 1×/week group, or 3×/week group following
completion of baseline assessments. Randomization was per-
formed offsite by a researcher who was not involved in testing
and training of participants using computer-generated ran-
domly permuted blocks (http://www.randomization.com/)
in blocks of six. Participants were stratified by years since
menopause (<5 years or ≥5 years rounded to the nearest
year), use of bone altering medication/supplements for the
prevention, and/or treatment of osteoporosis and habitual
physical activity over the past 3 months (y/n) defined as at
least 2 sessions/week of moderate-to high-intensity sport or
recreational activity other than casual walking. Participants
were informed of their group allocation by means of sealed
opaque envelopes given to them after completion of all
baseline testing, which they opened themselves.
2.4. Vibration Exposure. Participants who were asked to
remain in a standing position on a whole body vibration
device. The purpose built device produced a synchronous
vibration resulting in vertical acceleration, engineered by
Australian Catholic University. Low-frequency, low-magni-
tude vibration was applied (12Hz, 0.5mm peak-to-peak
displacement, 0.3 g), consistent with current research that
suggests that low magnitude is anabolic to bone [11] as it
does not cause damage to physiology associated with high-
magnitude vibration [25]. Past literature has reported that
low-frequency vibration (<25Hz) has greatest transmission
up the axial skeleton, with this transmissibility decreasing
as higher vibration frequencies are utilized [26, 27]. All
participants were instructed to stand on the vibration
platform with their feet shoulder width apart, knees locked,
and hands by their side to receive maximum vibration expo-
sure, as determined in a pilot study performed prior to and
during our study period (data not shown). The protocol
was performed with participants’ shoes removed to prevent
any attenuation of vibration that may result from footwear.
Participants were blinded to which groups were sham and
active. The sham platforms transmitted minimal vibration
(<0.1 g) but produced the same audible noise as the active
platforms. All of the vibration platforms were covered with
fabric to prevent participants from visually identifying active
or static platforms. Participants were told that any of the
three groups may experience improvements in the outcomes
measured and were not aware of the investigators hypotheses
regarding frequency of exposure effects.
Participants in the 1×/week and 3×/week groups were
required to attend sessions either once or three times a week
over eight weeks for 20 minutes of intermittent vibration,
respectively, during which time, vibration was applied for
one minute, followed by one minute of rest. The osteogenic
effect of vibration is reported to be greater when rest breaks
are incorporated into the vibration stimulus, as intermittent
exposure provides osteoblasts andmechanoreceptors of bone
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at rest from vibration stimulus, preventing insensitivity to
vibration that can occur during prolonged vibration expo-
sure [28]. The sham group attended training once a week and
received 20 minutes of a continuous sham vibration. Make-
up sessions were offered over a four-week period following
the initial 8-week program and thereby provided a 12-
week window in order to complete 100% of the prescribed
sessions.
2.5. Outcomes. Outcome measures were conducted at base-
line (before randomization) and at followup (completion of
8 sessions for Sham and 1×/week groups and 24 sessions for
3×/week group).
All outcomes were blindly assessed and analyzed at base-
line, as assessment occurred prior to randomization. Out-
comes assessed included anthropometric measures, demo-
graphic characteristics (including socioeconomic status,
smoking habits, and caffeine consumption), habitual phys-
ical activity, 25-OH vitamin D status, and body composition
measurement by bioelectric impedance analysis (fat-free
mass (FFM), skeletal muscle mass (SMM), fat mass (FM))
using standard equations for older adults [29].
2.5.1. Primary Outcomes. Markers of bone formation (bone-
specific alkaline phosphatase (ALP)) and resorption (N-tel-
opeptide X/Creatinine (NTx/Cr)) were assessed via blood
and urine tests performed without batching by an indepen-
dent laboratory that was blinded to group allocation. Blood
samples were collected between 72 and 120 hours following
the last vibration exposure session to standardize previously
reported acute bout effects on markers of bone metabolism
[30].
2.5.2. Compliance and Adverse Events. Compliance for each
participant was calculated as a percentage of the prescribed
sessions attended. Throughout the eight week study period,
a weekly questionnaire was completed in person or via phone
calls, in order to monitoring possible adverse effects from the
vibration exposure and any changes in health status.
2.5.3. Sample Size Calculations. Based on results from pre-
vious research investigating the anabolic effects of exercise
on bone markers [31] using an average estimate of difference
in bone-specific alkaline phosphatase (ALP) between control
and vibration-exposed participants of 2.9% (ES = −1.01),
a sample size of 13 per group was required for each of
the contrasting dose-response comparisons. This provided a
power of 0.80 at an alpha level of 0.05.
2.6. Statistical Analysis. Statistical analyses were performed
using StatView statistical software package (Version 5.0 SAS
Institute, Cary, NC). Data distributions were inspected for
normality. Normally distributed data were described using
mean± SD and non-normally distributed data using median
and ranges. Complete case analyses compared the differences
in primary and secondary outcomes between the 3×/week,
1×/week, and Sham control group using all available data
independent of compliance level. A secondary sensitivity
analysis was performed using an intention-to-treat analysis
with conservative imputation of results via last value carried
forward method. Analysis of covariance (ANCOVA) mod-
els were constructed to compare 3×/week, 1×/week, and
sham control groups, using the percentage change scores
(posttest − pretest/pretest × 100) as the dependent variable,
adjusted for baseline values of NTx/Cr and ALP. Variables
that were potentially related to the outcome of interest such
as age, month of assessment, percent change scores for
fat-free mass (FFM), skeletal muscle mass (SMM), body
weight, vitamin D, habitual physical activity, use of HRT,
and height at baseline were all identified a priori as potential
confounders of the treatment effect that could be used as
covariates in analysis of covariance (ANCOVA) models of
change scores. Variables with clinically importance between
group differences were included in ANCOVA models. Post-
hoc least significant difference (LSD) t-tests were used for
all pair-wise comparisons where appropriate (P < .05) to
ascertain specific group mean differences. Relationships
between continuous variables as potential predictors of
change in primary outcomes were analyzed with simple and
forward stepwise multiple linear regressionmodels. A P value
of <.05 and/or 95% confidence interval (CI) exclusive of
zero were accepted as statistically significant. Effect sizes
were judged as small, moderate, and large according to the
conventions of Cohen [32]. Clinical relevance was assessed
relative to the meaningfulness of bone and musculoskeletal
outcomes compared with existing literature.
3. Results
Recruitment and enrolment of 46 participants occurred from
May to July, 2007. Participant flow through the study is
presented in Figure 1.
3.1. Participant Characteristics. Baseline participant charac-
teristics are presented in Table 1. The cohort had a mean
age of 59.8 ± 6.2 years, with a median 7.3 years since
menopause. Thirty-seven percent of participants were over-
weight, and 4.4% participants were obese, with the majority
of participants having BMIs within the normal range. No
participants were classified as underweight [33]. Baseline
characteristics of the participants did not differ between
groups, except for height with participants in the sham
group shorter than the rest of the cohort. Osteoporosis, oste-
oporotic fractures, or osteopenia were present in 30% of
the total cohort, with osteopenia diagnosed in 15% of all
participants. Osteoarthritis was the highest reported comor-
bidity in this cohort (41%), with participants also report-
ing chronic musculoskeletal pain (22%) and hypercholes-
terolemia (13%) prior to commencement of the study.
Vitamin D status varied across the cohort, with the ma-
jority of participants within the normal range (80%); how-
ever, 20% were either classified as mildly or moderately
deficient. Following the 8-week study period, Vitamin D
levels decreased in all groups, with only 68% of participants
classified as normal and an increase in the number of women
who were mildly or moderately deficient (33%). This pattern
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Excluded (n = 59)
Enrolment
Randomization
n = 46
Allocation
Recruitment rate: 48/157 = 30.6%
Retention rate: 42/48 = 87.5%
Screened, future potential
(n = 26)
Potential subjects
(n = 157)
Reasons:
Not meeting inclusion criteria (n = 19)
Cannot commit (n = 9)
No longer interested (n = 18)
Other reasons (n = 13)
Followup
Lost to followup (n = 0)
Discontinued intervention (n = 2)
Reasons: Unhappy with
randomization
Lost to followup (n = 0)
Discontinued intervention (n = 1 )
Reason: poor health (unrelated to
intervention)
Lost to followup (n = 0)
Discontinued intervention (n = 1)
Reason: family illness
Assessed for eligibility (n = 131)
(i) Telephone screen
Screened (n = 131)
Excluded (n = 59)
(ii) Baseline assessment (n = 48)
Drop outs prior to
randomization:
(n = 2)
Control group n = 16
Allocated to intervention
(n = 16)
Received allocated intervention
(n = 15)
Did not receive allocated intervention
(n = 1)
Give reasons: Randomization error
One day/wk group n = 14
Allocated to intervention
(n = 14)
Received allocated intervention
(n = 13)
Did not receive allocated intervention
(n = 1)
Give reasons: Randomization error
3 day/wk group n = 16
Allocated to intervention
(n = 16)
Received allocated intervention
(n = 16)
Did not receive allocated intervention
(n = 0)
Figure 1: Recruitment flowchart.
is consistent with expected seasonal change, in which vitamin
D levels tend to decrease over winter months [34].
The NTx/Cr levels were not different between women
stratified by years since menopause (P = .92), vitamin D
category (normal, mildly, or moderately deficient) (P = .42),
and participation in regular physical activity (P = .95).
However, NTx/Cr was lower in women taking medications
that affected bone metabolism, consistent with lower levels
of bone resorption in these women (P = .03). Levels of
NTx/Cr were lower in women who were taking calcium
supplements (P = .01), bisphosphonates (P < .01), and
HRT (P = .09), compared with those not on these agents,
but vitamin D supplementation did not appear to influence
bone resorption (P = .58). Levels of NTx/Cr were higher in
participants without a diagnosis of osteoporosis, osteopenia
or osteoporotic fracture, who were not taking the above
bone-active agents (P = .03).
3.2. Outcomes
3.2.1. Bone Resorption. Following eight weeks of vibra-
tion exposure, NTx/Cr levels changed differentially among
the three groups. Specifically, NTx/Cr decreased in the
1×/week and 3×/week groups and increased in the sham
group, indicating a significant effect of group allocation
on bone resorption when compared by repeated measures
ANOVA (P < .03). Results are presented in Table 2. The
change in NTx/Cr was associated with baseline NTx/Cr val-
ues but not with any other participant characteristics at
baseline or with changes in any participant characteristics.
When baseline differences in age, height, NTx/Cr values,
use of HRT, and years since menopause were included as
covariates in an ANCOVA model (Figure 2), the change
in NTx/Cr was different between the 3×/week and sham
groups with a net decrease in the 3×/week group of 34.6%
(mean difference −12.6 nm/mm Cr, P < .01). The change
in NTx/Cr did not differ significantly between the active
platform groups (P = .21) or between the 1×/week group
and sham group (P = .12).
3.2.2. Bone Formation. The bone formation marker, ALP,
tended to decrease in all groups over the eight-week period
(P = .08), and no group effect on this change was observed
Journal of Osteoporosis 5
Table 1: Demographics and health status.
Variable
Whole cohort
(n = 46) Sham (n = 16)
1×/wk
(n = 14)
3×/wk
(n = 16)
Age (yrs) 59.8± 6.2 59.8 ± 5.2 60.9 ± 6.5 58.9 ± 7.1
Height (cm) 160.2± 5.8 156.9 ± 4.9 162.5 ± 4.6 161.6 ± 6.2
Body weight (kg)
62.80
(51.7–96.7)
62.15
(54.10–71.20)
64.67
(57.20–96.77)
62.88
(51.70–78.57)
Body mass index (kg/m2)§
24.38
(20.76–37.33)
25.22
(23.191–27.79)
24.64
(20.76–37.33)
23.62
(21.09–32.70)
History of smoking (%) 32.6 28.6 31.3 37.5
Number of medications/day 3.3 ± 2.6 3.2 ± 3.2 3.8 ± 3.3 2.5 ± 3.5
Vitamin D prescription (%) 17.4 12.5 14.3 25.0
Calcium prescription (%) 43.5 50.0 28.6 50.0
Bisphosphonate prescription (%) 13.0 6.3 14.3 18.8
HRT prescription (%) 8.7 0.0 14.3 12.5
Years since menopause
7.25
(2.00–37.00)
9.75
(2.00–30.00)
6.25
(3.50–37.00)
6.50
(2.50–31.00)
Participation in regular
structured exercise (%)
71.7 68.8 71.4 75.0
History of osteoporosis,
osteopenia, or osteoporotic
fracture
30.4 18.8 28.6 43.8
All data presented as mean ± SD for normally distributed data or median (range) for nonnormally distributed data unless otherwise specified.
§Body mass index: an indicator of body fat calculated by weight (kg)/Height (m)2. Normal values range from 18.5 to 24.9 kg/m2. Values ≥25 kg/m2 are
considered overweight and ≥30 kg/m2 obese.
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Figure 2: Group effect: Absolute changes in NTx/Cr (nm/mmCr)
values presented as Mean ± SD. Analysis by ANCOVA model with
changes score as dependent variable and group assignment, baseline
value of Ntx/Cr, age, height, use of HRT, and years since menopause
as independent variables. Group effect for model was P < .05,
post-hoc pair-wise comparisons analyzed by post-hoc LSD t-tests.
∗Indicates significance (P < .018) between the Sham and 3×/week
group.
(P = .27) when compared by repeated measures ANOVA
(Table 2). The group effect remained nonsignificant follow-
ing adjustment for age, height, baseline NTx values, use
of HRT, and years since menopause in ANCOVA mod-
els. Changes in bone formation were not associated with
participant characteristics at baseline or by changes in any
participant characteristics.
3.2.3. Secondary Analyses. Due to low numbers not handled
by stratification, the number of participants taking bis-
phosphonates and on HRT therapy were uneven between
groups. In order to correct for any bias due to the potential
confounding effect of bisphosphonate and HRT use on bone
metabolism, secondary analysis was conducted excluding
those participants (n = 10). In this analysis, NTx/Cr levels
did not change differentially among the three groups when
compared by repeated measures ANOVA. When change
scores were analyzed using an ANCOVA model, adjusting
for baseline differences in age, height, NTx/Cr values, and
years since menopause as covariates, the change in NTx/Cr
remained different between the 3×/week and sham groups
with a net decrease in the 3x/week group of 32.1% (P < .03).
The change in NTx/Cr did not differ significantly between
the active platform groups (P = .22) or between the 1×/week
group and sham group (P = .33). Data were missing for
NTx and ALP in 4 (8.7%) participants, due to dropout.
A secondary sensitivity analysis using an intention-to-treat
model with imputation of data failed to yield any significant
groups effects on markers of bone resorption and formation
(data not shown).
3.2.4. Compliance. In the three study groups, the reported
median vibration training compliance was 100 (0–100%),
with 87.5% of randomized participants completing the
study. One participant in the sham group withdrew from
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the study due to family illness, one participant in the
1×/week group withdrew due to illness and family problems,
and two participants in the 3×/week group withdrew prior
to their first vibration exposure session due to inability to
commit to study requirements.
3.2.5. Adverse Events. Adverse effects were reported by five
participants over the course of the study. Three participants
reported dizziness while standing on the vibration platform
(sham, n = 2; 3×/week, n = 1); one subject reported feeling
faint and was unable to complete 20 minutes of vibration
(1×/week, n = 1). One subject reported shoulder pain
following baseline muscle strength testing, which persisted
for the duration of the study (1×/week, n = 1).
4. Discussion
In this study, we investigated the frequency dose-response
relationship of whole body vibration stimulus on markers
of bone turnover in postmenopausal women in a com-
munity setting. We showed, for the first time, that low-
magnitude, low-frequency vibration exposure (0.3 g) 3 times
per week reduced a marker of bone resorption (NTx/Cr)
in postmenopausal women. The net decrease in NTx/Cr in
the 3×/week group compared with the sham group was
34.6%, which was not only statistically significant, but also
potentially clinically meaningful. The magnitude of effect
remained large (32.1%) when participants taking bispho-
sphonates and on HRT were removed from the analysis.
By comparison, reductions of 25% in markers of bone
resorption have been reported in postmenopausal women
with osteoporosis/osteopenia following walking programs
of 12-month duration [35] and long-term pharmacological
treatment [36]. We did not observe an effect of vibration
exposure at either frequency on bone formation as assessed
by ALP.
4.1. Bone Resorption Markers. Only one previous study by
Iwamoto et al. has investigated the effects of vibration on
urinary NTx, reporting a nonsignificant decrease following
high frequency, low-magnitude vibration exposure over 12
months [12]. The magnitude of vibration in Iwamoto’s
study was higher than in ours; however, the exposure was
only 4 minutes 1×/week and their study investigated addi-
tional effects of vibration in participants who were also
taking Alendronate, a bisphosphonate with strong bone pro-
tective effects of reducing bone resorption by up to 5%
following long-term use [36]. A lack of comparison between
a vibration group and a control group in the absence of
alendronate administration makes it difficult to determine
whether there was any isolated effect of low-magnitude
vibration on bone resorption. Two studies have investigated
other markers of bone resorption (serum C-telopeptide X
[16, 17] and Tartrate-resistant acid phosphatase-5b [16]),
without significant effects of vibration after 6–8 months of
exposure. Thus, the present study is the first to report signif-
icant changes in bone resorption following low-magnitude
vibration exposure.
Our study suggests a dose-response relationship between
vibration exposure and reduced bone resorption. Specif-
ically, vibration exposure 3×/week significantly reduced
NTx/Cr when compared with the sham group, but this dif-
ference was not seen in the 1×/week group. A large effect
size suggests that sample size was adequate to highlight
group differences between the 3×/week and sham group
(ES = −0.96). However, a small effect size was obtained
when comparing the 1×/week group to the sham group,
with low statistical power a potential factor in this lack of
significance. Larger studies are needed to confirm this lack
of efficacy of once-weekly training. However, it remains un-
known whether vibration stimulus 3×/week is optimal or
whether similar or greater changes in NTx/Cr could be
achieved with higher exposure to vibration (number of days
per week or minutes per session).
4.2. Bone Formation Markers. The bone formation marker
ALP decreased similarly in all groups over the study period,
which may be explained by the late autumn to winter
period of recruitment into the study [37]. No studies have
investigated the effects of vibration on ALP, but nonsignifi-
cant reductions in osteocalcin, another marker of bone for-
mation [16, 17], have been reported. It is also possible
that osteocalcin, a more specific marker of bone formation
than ALP, is more sensitive to changes in bone formation
resulting from vibration exposure. A nonsignificant decrease
in osteocalcin following 6 months of high-frequency, high-
amplitude vibration has been reported in postmenopausal
women [17]. The effect size for this change was large (ES =
−0.95), suggesting that the study was adequately powered to
identify group differences between the vibration and control
groups. This is the only study in humans that has shown
a potential negative effect of vibration on markers of bone
formation. However, this result is consistent with reports
by Rubin indicating that high-amplitude vibration may be
catabolic to bone [26]. A decrease in bone mineral density
was not found by Verschueren et al., but this may be due to
the short duration of the study (6 months). Thus, further
research is required to determine if this potential catabolic
effect of high amplitude vibration on bone is consistent and
related to duration of exposure.
The lack of improvement in bone formation markers
observed in our study is consistent with previous research
in older adults. The effect size for changes in ALP between
groups in our study were small, suggesting that a larger
sample size was required to find a group effect, if one
existed, on bone formation levels. The significant reduction
in the bone resorption marker we observed is a novel finding
after vibration exposure in humans. Notably, the biological
plausibility of this finding is supported by a recent study
of murine osteocytes in which low-magnitude (0.3 g), high-
frequency vibration similar to our protocol increased soluble
inhibitors of osteoclast formation at both the transcript and
protein level. Resorption activity of the exposed osteocytes
was also lowered in response to this vibration stimulus [38].
Large consumption of caffeine is associated with increas-
ed risk of osteoporosis and decreased bone formation [39].
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This relationship was not found in this cohort with bone for-
mation being similar in participants who consumedmultiple
cups of caffeinated drinks per day and those who refrained
from caffeine consumption.
Compliance for traditional treatments for osteoporosis,
including pharmacological aids, have been shown to be low
in previous studies [40], and this may be attributed to risks
associated with prolonged use of some treatments, such as
increased risk of breast and uterine cancers [41]. Compliance
in our study was high across all three groups (median 100%;
range 0–100%), which is consistent with compliance found
in other studies [42], highlighting the potential feasibility of
vibration exposure in postmenopausal, community-dwelling
women.
Limitations to this study include sample size and inter-
vention. The intervention period of eight weeks may not have
been sufficient to observe larger effects on markers of bone
metabolism. Previous studies have shown changes in bone
outcomes typically occur over longer intervention periods,
especially if architectural changes in bone are to be observed
[9–11, 15–17]. Optimal dose and duration of vibration
exposure remains unknown, and it is recommended that ad-
ditional studies be conducted. Our secondary, unplanned
analysis with bisphosphonate and HRT users excluded did
not show a significant effect of vibration on resorption
using repeated measures ANOVA. This is likely due to type
II error as the magnitude of effect is similar with these
participants excluded. As, by design, the dosages of bone
altering medications remained constant throughout the
study constant, our results suggest that the observed effect
is due to the vibration exposure, rather than an effect of the
medication.
Vibration exposure protocols have varied widely in all
studies to date investigating the effect of vibration on bone
outcomes. While our study compared two vibration inter-
vention groups differing in the number of sessions per week,
no human studies have directly investigated if any differences
exist in bone outcomes between continuous and intermittent
vibration or if a difference exists in the effect of vibration
on bone in participants standing still on the platform
compared with participants performing dynamic and static
exercise while on the platform. Another underexplored
aspect of the research is the direction of vibration that
elicits the greatest gains in bone outcomes, that is, reciprocal
or oscillating. At present, no standard approach exists to
counteract the attenuation effects of wearing footwear while
on the vibration platform and differences between receiving
vibration exposure while wearing shoes or while barefoot,
as well as with locked, soft, or flexed knee positions should
be investigated. Future research needs to establish wheth-
er vibration exposure effects on bone are retained after the
vibration stimulus is removed, and the time course of de-
training. It is unknown whether gender, nutritional status,
hormonal status, bone density, or use of medications af-
fecting bone remodeling influences the efficacy of vibration
exposure, and studies comparing responses across such
cohorts are required. Finally, the molecular mechanisms
which may underlie vibration effects on bone turnover are
largely unknown.
5. Conclusion
Low-frequency, low-magnitude vibration (12Hz, 0.3 g) three
times a week leads to a potentially clinically meaningful
34.6% reduction in NTx/Cr, a marker of bone resorption,
whereas one day per week exposure appears insufficient.
Further studies are required to extend and confirm these
findings, determine the optimal dose of vibration exposure,
and determine whether this decreased resorption is sustained
and ultimately leads to increased bone density, tensile
strength, and reduced risk of fragility fracture. The effect
of long-term vibration on bone resorption may be clinically
relevant if the changes we observed after 24 sessions were to
be sustained or magnified with greater vibration dosage.
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